Analytical Data
-
Gene name
GCH1
- Application
-
Alternative Names
GCH1；DYT5；GCH；GTP cyclohydrolase 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P30793
-
Expression Region
1-250aa
-
AA Sequence
MEKGPVRAPA EKPRGARCSN GFPERDPPRP GPSRPAEKPP RPEAKSAQPA DGWKGERPRS EEDNELNLPN LAAAYSSILS SLGENPQRQG LLKTPWRAAS AMQFFTKGYQ ETISDVLNDA IFDEDHDEMV IVKDIDMFSM CEHHLVPFVG KVHIGYLPNK QVLGLSKLAR IVEIYSRRLQ VQERLTKQIA VAITEALRPA GVGVVVEATH MCMVMRGVQK MNSKTVTSTM LGVFREDPKT REEFLTLIRS
-
Molecular Weight
27.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GCH1 (GTP cyclohydrolase 1) is a crucial enzyme involved in the biosynthesis of tetrahydrobiopterin (BH4), an essential cofactor for a variety of biological processes, including the production of neurotransmitters like dopamine and serotonin. Mutations in the GCH1 gene can lead to a range of neurological disorders, most notably dopa-responsive dystonia, which is characterized by movement disorders and other neurological symptoms. Research into GCH1 recombinant protein has gained significant attention due to its potential therapeutic implications. By producing and characterizing recombinant GCH1, scientists aim to better understand the enzyme's structure-function relationship and the effects of different mutations on its activity. This knowledge is vital for developing targeted treatments for conditions caused by GCH1 dysfunction. Additionally, studying the enzyme in a recombinant form allows for the exploration of its regulatory mechanisms and interactions with other proteins, shedding light on the broader biochemical pathways influenced by BH4. Overall, GCH1 recombinant protein research represents a promising avenue in both basic science and clinical applications, with the potential to inform novel therapeutic strategies for treating associated disorders.
